Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 7/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950816 | 0.99 | CA1 (0.44) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL21361102 | 0.98 | CA1 (0.42) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL14950994 | 0.97 | CA1 (0.43) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL14950932 | 0.97 | CA1 (0.43) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL23475889 | 0.97 | CTSK (0.44) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL16853378 | 0.97 | CTSK (0.44) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL28893925 | 0.97 | CTSK (0.44) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL23475976 | 0.97 | CTSK (0.44) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL18088380 | 0.90 | CA1 (0.39) | CA1CA2CTSSCTSKCAPN1 | |
| SCHEMBL19543629 | 0.88 | CTSS (0.53) | CA1CA2CTSSCTSKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413594-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | CA1 780/4885CA2 2328/4885CTSS 1191/4885 |
| US-10413594-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | CA1 780/4885CA2 2328/4885CTSS 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.